Panbela Therapeutics (PBLA) Competitors $0.16 +0.00 (+1.91%) As of 12:09 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. SNOA, GLTO, LIPO, MTNB, MBIO, RDHL, SNGX, INM, CNSP, and TTNPShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Sonoma Pharmaceuticals (SNOA), Galecto (GLTO), Lipella Pharmaceuticals (LIPO), Matinas Biopharma (MTNB), Mustang Bio (MBIO), Redhill Biopharma (RDHL), Soligenix (SNGX), InMed Pharmaceuticals (INM), CNS Pharmaceuticals (CNSP), and Titan Pharmaceuticals (TTNP). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors Sonoma Pharmaceuticals Galecto Lipella Pharmaceuticals Matinas Biopharma Mustang Bio Redhill Biopharma Soligenix InMed Pharmaceuticals CNS Pharmaceuticals Titan Pharmaceuticals Sonoma Pharmaceuticals (NASDAQ:SNOA) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation. Do institutionals and insiders believe in SNOA or PBLA? 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, SNOA or PBLA? Sonoma Pharmaceuticals has higher revenue and earnings than Panbela Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$14.29M0.34-$3.46M-$3.10-0.96Panbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Does the media prefer SNOA or PBLA? In the previous week, Sonoma Pharmaceuticals' average media sentiment score of 0.00 equaled Panbela Therapeutics'average media sentiment score. Company Overall Sentiment Sonoma Pharmaceuticals Neutral Panbela Therapeutics Neutral Which has more risk & volatility, SNOA or PBLA? Sonoma Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Is SNOA or PBLA more profitable? Panbela Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -24.23%. Panbela Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-24.23% -58.73% -21.05% Panbela Therapeutics N/A N/A -302.61% Do analysts prefer SNOA or PBLA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryPanbela Therapeutics beats Sonoma Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$777K$783.11M$5.50B$9.01BDividend YieldN/A4.84%5.39%4.11%P/E Ratio0.001.3027.4220.07Price / SalesN/A222.05398.50109.13Price / CashN/A23.4436.1356.90Price / Book-0.016.018.015.70Net Income-$25.26M-$27.64M$3.16B$248.47M7 Day Performance-23.81%0.35%2.08%2.92%1 Month Performance-46.67%6.82%4.38%5.77%1 Year Performance-55.81%7.77%35.81%21.39% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.0867 of 5 stars$0.16+1.9%N/A-56.6%$777KN/A0.006Gap UpSNOASonoma PharmaceuticalsN/A$2.93-0.3%N/A+1,143.6%$4.81M$14.29M-0.95180Positive NewsGLTOGalecto3.4039 of 5 stars$3.50+3.9%$10.00+185.7%-69.8%$4.63MN/A-0.2340Negative NewsGap DownLIPOLipella Pharmaceuticals2.0388 of 5 stars$1.02-7.3%N/A-77.4%$4.56M$540K-0.254MTNBMatinas Biopharma0.1367 of 5 stars$0.90+1.7%N/AN/A$4.55M$1.10M-0.1830Positive NewsMBIOMustang Bio1.071 of 5 stars$1.04+0.5%N/A-95.6%$4.53MN/A-0.01100News CoverageGap DownRDHLRedhill BiopharmaN/A$1.92+1.3%N/A-99.1%$4.39M$8.04M0.00210News CoverageSNGXSoligenix1.3775 of 5 stars$1.36-17.6%N/A-44.5%$4.39M$120K-0.3120Gap DownHigh Trading VolumeINMInMed Pharmaceuticals1.009 of 5 stars$3.58+45.9%N/A-38.9%$4.29M$4.92M-0.2910Gap UpHigh Trading VolumeCNSPCNS Pharmaceuticals1.8524 of 5 stars$0.76+0.1%$25.00+3,189.5%-98.5%$4.15MN/A0.005TTNPTitan Pharmaceuticals0.3167 of 5 stars$4.52+6.1%N/A-18.0%$4.11M$180K-0.9810 Related Companies and Tools Related Companies Sonoma Pharmaceuticals Competitors Galecto Competitors Lipella Pharmaceuticals Competitors Matinas Biopharma Competitors Mustang Bio Competitors Redhill Biopharma Competitors Soligenix Competitors InMed Pharmaceuticals Competitors CNS Pharmaceuticals Competitors Titan Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
